Does robot-assisted gait training ameliorate gait abnormalities in multiple sclerosis? A pilot randomized-control trial

2013 ◽  
Vol 33 (4) ◽  
pp. 555-563 ◽  
Author(s):  
S. Straudi ◽  
M.G. Benedetti ◽  
E. Venturini ◽  
M. Manca ◽  
C. Foti ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Randomized Control Trial ◽  
Gait Training ◽  
Robot Assisted ◽  
Randomized Control ◽  
Gait Abnormalities ◽  
Pilot Randomized Control Trial

Does robot-assisted gait training improve ambulation in highly disabled multiple sclerosis people? A pilot randomized control trial

2016 ◽  
Vol 23 (5) ◽  
pp. 696-703 ◽  
Author(s):  
Alessandra Pompa ◽  
Giovanni Morone ◽  
Marco Iosa ◽  
Luca Pace ◽  
Sheila Catani ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Outcome Measures ◽  
Primary Outcome ◽  
Controlled Trial ◽  
Gait Training ◽  
Control Group ◽  
Robot Assisted ◽  
Robotic Training ◽  
Global Mobility ◽  
Pilot Randomized Control Trial

Background: Robotic training is commonly used to assist walking training in patients affected by multiple sclerosis (MS) with non-conclusive results. Objective: To compare the effect of robot-assisted gait training (RAGT) with that of conventional walking training (CWT) on gait competencies, global ability, fatigue and spasticity in a group of severely affected patients with MS. Methods: A pilot, single-blind randomized controlled trial was conducted in 43 severe (Expanded Disability Status Scale (EDSS) score of 6–7.5) and non-autonomous ambulant in-patients with MS. Experimental group performed 12 sessions of RAGT, whereas control group performed the same amount of CWT. Primary outcome measures were gait ability assessed by 2 minutes walking test and Functional Ambulatory Category; secondary outcomes were global ability (modified Barthel Index), global mobility (Rivermead Mobility Index), severity of disease (EDSS) and subjectively perceived fatigue (Fatigue Severity Scale). Results: The number of subjects who achieved a clinical significant improvement was significantly higher in RAGT than in CWT ( p < 0.05 for both primary outcome measures). RAGT also led to an improvement in all the other clinical parameters (global ability: p < 0.001, global mobility: p < 0.001, EDSS: p = 0.014 and fatigue: p = 0.001). Conclusions: RAGT improved the walking competencies in non-autonomous ambulant patients with MS, with benefits in terms of perceived fatigue.

Fall risk and incidence reduction in high risk individuals with multiple sclerosis: a pilot randomized control trial

2014 ◽  
Vol 29 (10) ◽  
pp. 952-960 ◽  
Author(s):  
Jacob J Sosnoff ◽  
Yaejin Moon ◽  
Douglas A Wajda ◽  
Marcia L Finlayson ◽  
Edward McAuley ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
High Risk ◽  
Randomized Control Trial ◽  
Fall Risk ◽  
Randomized Control ◽  
Pilot Randomized Control Trial

The effects of robot-assisted gait training on locomotor function in subjects with multiple sclerosis: A three months follow-up study

2011 ◽  
Vol 33 ◽  
pp. S12-S13 ◽  
Author(s):  
E. Venturini ◽  
L. Balugani ◽  
F. Zarattin ◽  
G. Ferraresi ◽  
S. Straudi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Gait Training ◽  
Robot Assisted ◽  
Locomotor Function ◽  
Follow Up Study

IOTG-02. Glioma Supra Marginal Incision Trial (G-SUMIT): a phase II pilot randomized control trial to assess the feasibility of “supra-marginal” surgical resection of malignant glioma

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi227-vi227
Author(s):  
Carolyn Lai ◽  
Alireza Mansouri ◽  
Damon Scales ◽  
James Perry ◽  
Arjun Sahgal ◽  
...  
Keyword(s):  
Surgical Resection ◽  
Phase Ii ◽  
Randomized Control Trial ◽  
Survival Benefit ◽  
Safety Data ◽  
Anatomical Location ◽  
Karnofsky Performance Score ◽  
High Grade ◽  
Randomized Control ◽  
Pilot Randomized Control Trial

Abstract High grade gliomas are the most common primary malignant brain tumor in adults having a median survival of only 13–16 months. This is despite the current standard of maximal safe surgical resection followed by fractionated radiotherapy and chemotherapy. Extending the tumor resection limit beyond the GAD-enhancing margin (i.e. supra-marginal resection) could in principle provide an added survival benefit as it has been shown that &gt;80% of post-operative tumor recurrence is within a 2cm region surrounding the original GAD-enhancing margin. However, this must be weighed against the risk of potential damage to functional brain tissue. In this phase II pilot randomized control trial (RCT), we aim to assess the feasibility of “supra-marginal” resection extending 1cm beyond the enhancing tumor in adults with radiographic evidence of GAD-enhancing intra-axial tumour consistent with high grade glioma in a safe anatomical location and a Karnofsky Performance Score &gt; 60. With six academic centres participating, we aim to enroll 72 patients over two years. Currently, four patients have already been enrolled in the first four months. Primary outcomes include evaluating the feasibility of performing a large-scale trial with regards to recruitment, allocation and outcome documentation as well as safety data. Secondary outcomes include determining if there is an increased survival benefit with supra-marginal resection and impact on quality of life. Our pilot RCT will test the feasibility of comparing standard gross total resection of GAD-enhancing tumour and supra-marginal resection to prepare for a larger definitive multicentre RCT.

Coping power for preschool-aged children: a pilot randomized control trial study

2016 ◽  
Vol 11 (6) ◽  
pp. 532-538 ◽  
Author(s):  
Pietro Muratori ◽  
Consuelo Giuli ◽  
Iacopo Bertacchi ◽  
Lara Orsolini ◽  
Laura Ruglioni ◽  
...  
Keyword(s):  
Randomized Control Trial ◽  
Randomized Control ◽  
Coping Power ◽  
Pilot Randomized Control Trial ◽  
Preschool Aged Children
Sign in / Sign up

Export Citation Format

Share Document